FDA Approves Pancreatic Enzyme Products to Aid Digestion

02 Mar 2012 --- Ultresa is a delayed-release capsule used to treat children and adults with cystic fibrosis, a serious genetic disorder affecting the lungs and other organs, or other conditions who cannot digest food normally because their pancreas does not make enough pancreatic enzymes.

Mar 2 2012 --- Two new pancreatic enzyme products used to help aid food digestion, Ultresa (pancrelipase) and Viokace (pancrelipase), were approved by the U.S. Food and Drug Administration.

Ultresa is a delayed-release capsule used to treat children and adults with cystic fibrosis, a serious genetic disorder affecting the lungs and other organs, or other conditions who cannot digest food normally because their pancreas does not make enough pancreatic enzymes.

Viokace, in combination with a proton pump inhibitor, is used to treat adults who cannot digest food normally. Adults with chronic pancreatitis, a continuing, chronic inflammatory process of the pancreas, or those who have had some or all of their pancreases removed (pancreatectomy) may not digest food normally because they lack needed enzymes or because their enzymes are not released into the bowel (intestine). Viokace’s safety and efficacy in children has not been established.

“The approvals of Ultresa and Viokace, along with the other approved pancreatic enzyme products, allow health care providers to prescribe the product that is most appropriate for the estimated 200,000 patients in the United States who have pancreatic insufficiency,” said Julie Beitz, M.D., director of the Office of Drug Evaluation III in FDA’s Center for Drug Evaluation and Research.

Ultresa and Viokace are the fourth and fifth pancreatic enzyme products approved by FDA. Other FDA-approved pancreatic enzyme products include Creon (2009), Zenpep (2009) and Pancreaze (2010). Approved pancreatic enzyme products meet FDA standards for safety, efficacy and product quality.

Unapproved pancreatic enzyme products had been available for many years. FDA established a date of April 28, 2010 for the makers of pancreatic enzyme products to stop manufacturing and distributing unapproved products.

Ultresa and Viokace are marketed by Bridgewater, N.J.-based Aptalis Pharma U.S. Inc.
 

Related Articles

Health & Nutrition News

Scientists Have Discovered Potent Anti-Inflammatory Effects of Sage and Rosemary

29 Jul 2016 --- Two plant-derived compounds found in sage and rosemary may be effective for fighting inflammation and pain, according to new research. Diterpenoids are found in certain plants, fungi and marine organisms with two in particular, carnosol (CS) and carnosic acid (CA), known to interfere with multiple pathways in the human body association with pain and inflammation.

Health & Nutrition News

Diabetes UK Welcomes Tesco Free Fruit for Kids Initiative

29 Jul 2016 --- Tesco has announced that it will be offering free fruit to children across the UK. Launching in over 800 stores, the initiative means it’s even easier for children to get their five a day.

Health & Nutrition News

FDA Approves Adlyxin to Treat Type 2 Diabetes

29 Jul 2016 ---The US Food and Drug Administration approved Adlyxin (lixisenatide), a once-daily injection to improve glycemic control (blood sugar levels), along with diet and exercise, in adults with type 2 diabetes.

Health & Nutrition News

Scientific Studies Confirm Benefits of BENEO's Synergy1 in Reducing Diabetes Risk

28 Jul 2016 --- Two new research studies, conducted by Professor Gary Frost and his team from Imperial College London, have shown major beneficial effects of BENEO’s chicory root fiber OraftiSynergy1 (oligofructose-enriched inulin) in reducing the risk of diabetes. With approximately 415 million diabetic people worldwide and predictions that these numbers will rise dramatically in the coming years, the new findings are of great relevance.

More Articles
URL : http://www.nutritioninsight.com:80/news/FDA-Approves-Pancreatic-Enzyme-Products-to-Aid-Digestion.html